Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,615 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sleep-Wake Disorders Clear all

Conditions: Circadian Rhythm Sleep Disorders
Interventions: VEC-162; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Restless Legs Syndrome
Interventions: GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Nocturia, Insomnia
Interventions: Integrated Behavioral Therapy Program, Health Education Program; Behavioral
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 60 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Atlanta, Georgia

Conditions: Obstructive Sleep Apnea
Interventions: AD182, AD504, Placebo, Polysomnography; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Post-traumatic Stress Disorder, Insomnia
Interventions: pimavanserin, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson's Disease, Insomnia
Interventions: eszopiclone, placebo; Drug · Other
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 35 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Suwanee, Georgia • Edison, New Jersey • Piscataway, New Jersey + 1 more

Conditions: ADHD, Sleep Problems
Interventions: Ferrous Sulfate, Placebo; Dietary Supplement · Other
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 8 Years to 18 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insomnia
Interventions: Gabapentin; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 14 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obstructive Sleep Apnea
Interventions: Awake endoscopy; Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions: Pitolisant Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: ropinirole Extended Release (XR); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 28
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 25 more

Conditions: Diabetes Mellitus Type 2
Interventions: Positive Airway Pressure therapy, Lifestyle counseling; Device · Behavioral
Lead sponsor: ResMed; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more

Conditions: Sleep Apnea, Obstructive Sleep Apnea
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: North Haven, Connecticut

Conditions: Chronic Widespread Pain, Chronic Insomnia
Interventions: Cognitive Behavioral Therapy for Chronic Widespread Pain; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions: ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 34
States / cities: Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more

Conditions: Idiopathic Hypersomnia
Interventions: ALKS 2680, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 34
States / cities: Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: REM Sleep Behavior Disorder
Interventions: Natural progression over time; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sleep Problems
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Years to 9 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Houston, Texas

Conditions: Dementia
Interventions: Sleep Education Program; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obstructive Sleep Apnea
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obstructive Sleep Apnea, Hypertension
Interventions: AD113, Atomoxetine; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Towson, Maryland • Cincinnati, Ohio • Columbia, South Carolina

Conditions: Quality of Life, Obesity, Sleep Quality
Interventions: Placebo, Pep19 2 mg, Pep19 5 mg; Dietary Supplement
Lead sponsor: Proteimax Biotechnology Israel LTD; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Sunrise, Florida

Conditions: Restless Legs Syndrome
Interventions: equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml, Normal saline - 1ml; Drug
Lead sponsor: Lowcountry Infectious Diseases; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obstructive Sleep Apnea
Interventions: Inspire Upper Airway Stimulation System; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 15
States / cities: Palo Alto, California • St. Petersburg, Florida • Tampa, Florida + 12 more

Search by objective public record fields.

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

Multi-center Trial to Improve Nocturia and Sleep in Older Adults

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Pimavanserin for Insomnia in Veterans With PTSD

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

Gabapentin's Effects on Insomnia in Patients With Recent Concussion

Prospective Use of Awake Endoscopy for Inspire Activation

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea

Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Neuroplasticity in RBD

Understanding Sleep Problems in Children With Autism Spectrum Disorder

Behavioral Sleep Intervention in Adult Family Homes

The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Effect of Consumption of Pep19 on Quality of Life

Neuroma Injections to Treat Restless Legs Syndrome - RCT

Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)